Senses Disorder TRIZ Cases

Hot extrusion creates amorphous N-alkylamide solid dispersions for enhanced solubility.

N-alkylamides stimulate endothelial nitric oxide synthase transcription to raise nitric oxide levels.

Modified AAV virions use a peptide insertion in the GH loop to enhance retinal cell infectivity.

Cost-effective small molecules replace expensive antibody treatments by inhibiting VEGFR2 to treat wet macular degeneration.

Cysteine persulfide and glutathione persulfide suppress oxidative stress, preventing corneal opacity and retinal cell death.

A growth hormone variant combined with an antisense oligonucleotide reduces serum insulin-like growth factor I levels.

Polymeric anti-VEGF antibody conjugates extend therapeutic half-life to reduce intravitreal injection frequency.

Topical BDNF eyedrops use tamarind seed viscosity to increase retinal absorption, preventing photoreceptor degeneration without invasive injections.

Small molecule Kv1.3 inhibitors target effector memory T-cells to treat autoimmune diseases.

Integrin-disrupting molecules convert Ang2 into a Tie2 agonist to stabilize endothelial junctions and reduce vascular permeability.

A recombinant adeno-associated virus formulation uses citrate buffer, amino acids, sugars, and surfactants to maintain viral purity.

Capsiate regulates cytokine production and alleviates symptoms by converting initial irritation into a therapeutic response without side effects.

Chlamydomonas reinhardtii extract antagonizes adrenergic receptors to treat angina and glaucoma without complex purification steps.

Phenylquinoline derivatives enhance PPARα binding affinity to reduce retinal inflammation and neovascularization without off-target side effects.

A gene therapy approach using AAV vectors restores auditory and vestibular functions in mature inner ear hair cells.

Non-oral CGRP receptor antagonists bypass first-pass liver metabolism to reduce toxicity while maintaining high affinity.

Chemically modified synthetic miR-29 mimetics reverse pulmonary fibrosis by restoring target gene regulation.

N-hydroxyamidino compounds block indoleamine 2,3-dioxygenase to prevent tryptophan degradation and reduce immunosuppression.

Macrocyclic compounds inhibit factor XIa and plasma kallikrein, replacing polar groups to improve oral bioavailability.

AAV8 capsid mutations at positions 587-595 improve bipolar cell targeting while maintaining overall transduction efficiency.

N-(N-acetylcysteinyl-)chitosan extends ocular residence time through mucoadhesion, alleviating dry eye symptoms for up to 24 hours with a single application.

Optimized antibody sequences lower aggregation tendency, enabling stable high-concentration formulations for continuous treatment.

Merges DPP-4 inhibition with basal insulin coverage to maintain long-term glycemic control while minimizing adverse effects.

Spirocyclic acylguanidines inhibit beta-secretase while avoiding hERG channel binding and phospholipidosis.

Albumin nanoparticle minocycline formulations concentrate therapeutic agents in brain tissue.

TAK-1 inhibitors prevent proliferative vitreoretinopathy scarring by blocking epithelial-mesenchymal transition during retinal detachment surgery.

A sequential regimen using a GLP-1 receptor agonist followed by a DPP-4 inhibitor reduces body weight and sustains glycemic control.

Deuterated pentoxifylline compositions modulate CYP450-mediated metabolism to reduce toxic metabolite accumulation in renal impairment patients.

Orally disintegrating lutein ester tablets absorb through the oral mucosa, bypassing gastric acid degradation that reduces supplement effectiveness.

Selective p38 MAP kinase inhibitors block myofibroblast activity to minimize scar tissue formation during wound repair.

Antioxidant extracts neutralize free radicals to slow cataract progression in aging pets.

5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives act as non-peptide antagonists for both human orexin OX1 and OX2 receptors.

3-amino-6-chloro-pyrazine derivatives inhibit epithelial sodium channels with high solubility.

Spherical 20-40 µm poly(D,L-lactide) microparticles reduce viscosity and needle blockage during uveitis treatment.

Modified tripeptide structures improve metabolic stability and bioavailability to treat inflammatory diseases without toxic side effects.

An oil-in-water emulsion delivers antisense oligonucleotide GS-101 to inhibit IRS-1 expression and prevent corneal neovascularization.

Position-specific triazole substituents achieve selective 11β-HSD1 inhibition, reducing drug interaction risks while treating metabolic disorders.

Azabicyclic carboxamide derivatives improve functional activity and safety profiles by modifying bicyclic heteroaryl cores to reduce off-target effects.

Iminothiazine compounds inhibit BACE enzymes, reducing amyloid beta production to address underlying Alzheimer's disease causes.

Isolating PMLs from peripheral blood resolves poor migration and high dose requirements.

Peptides activate the guanylate cyclase C receptor to treat irritable bowel syndrome and reduce inflammation.

IL-34 cytokine protects neural retina from degeneration by modulating microglial homeostasis, avoiding corticosteroid side effects.